Skip to main content
Top
Published in: Clinical and Translational Oncology 2/2017

01-02-2017 | Research Article

Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience

Authors: E. Kempf, G. Desamericq, B. Vieites, I. Diaz-Padilla, E. Calvo, P. Estevez, A. Garcia-Arreza, M.A. Martinez-Maestre, I. Duran

Published in: Clinical and Translational Oncology | Issue 2/2017

Login to get access

Abstract

Purpose

Non-epithelial ovarian cancers (NEOCs) are rare diseases. Despite their overall good prognosis, the best management and current prognostic factors remain unclear. The objective of our study was to assess the clinical and pathological features of NEOC patients treated in our institution in the last 15 years and to explore risk factors for relapse and survival.

Methods/patients

All patients with a pathological diagnosis of NEOC referred to the medical oncology department at Hospital Universitario Virgen del Rocio between 1999 and 2014 were included. Demographics, tumor characteristics, treatment procedures, and clinical follow-up were retrospectively collected. Risk factors for disease-free survival (DFS) and overall survival (OS) were assessed.

Results

Fifty-seven patients were included, 33 (58 %) had a sex cord-stromal tumor (SCST) and 24 (42 %) had a germ-cell tumor (GCT). Median age, non-conservative surgery rates and DFS were lower in the GCT cohort; however, salvage chemotherapy led to a high proportion of complete responses in this group translating into a 90 % 3-year OS rate in both NEOC subtypes. The only identified risk factors statistically significant were stage and tumour relapse that associated, respectively, with DFS (HR = 8.84; 95 % CI 1.85–42) and OS (HR = 11.02; 95 % CI 1.76–68.7).

Conclusions

Despite their rarity, NEOCs remain a highly curable group of neoplasm. In our series, a more conservative treatment approach in ovarian GCTs revealed comparable OS outcomes to SCST. No new risk factors that would help in patient stratification were identified.
Literature
1.
go back to reference Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol. 2005;97(2):519–23.CrossRefPubMed Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol. 2005;97(2):519–23.CrossRefPubMed
2.
go back to reference Stettner AR, Hartenbach EM, Schink JC, Huddart R, Becker J, Pauli R, et al. Familial ovarian germ cell cancer: report and review. Am J Med Genet. 1999;84(1):43–6.CrossRefPubMed Stettner AR, Hartenbach EM, Schink JC, Huddart R, Becker J, Pauli R, et al. Familial ovarian germ cell cancer: report and review. Am J Med Genet. 1999;84(1):43–6.CrossRefPubMed
3.
go back to reference Giambartolomei C, Mueller CM, Greene MH, Korde LA. A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome. Cancer Epidemiol. 2009;33(1):31–6.CrossRefPubMedPubMedCentral Giambartolomei C, Mueller CM, Greene MH, Korde LA. A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome. Cancer Epidemiol. 2009;33(1):31–6.CrossRefPubMedPubMedCentral
4.
go back to reference Van Nieuwenhuysen E, Lambrechts S, Lambrechts D, Leunen K, Amant F, Vergote I. Genetic changes in nonepithelial ovarian cancer. Expert Rev Anticancer Ther. 2013;13(7):871–82.CrossRefPubMed Van Nieuwenhuysen E, Lambrechts S, Lambrechts D, Leunen K, Amant F, Vergote I. Genetic changes in nonepithelial ovarian cancer. Expert Rev Anticancer Ther. 2013;13(7):871–82.CrossRefPubMed
5.
go back to reference Kraggerud SM, Hoei-Hansen CE, Alagaratnam S, Skotheim RI, Abeler VM, Rajpert-De Meyts E, et al. Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr Rev. 2013;34(3):339–76.CrossRefPubMedPubMedCentral Kraggerud SM, Hoei-Hansen CE, Alagaratnam S, Skotheim RI, Abeler VM, Rajpert-De Meyts E, et al. Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr Rev. 2013;34(3):339–76.CrossRefPubMedPubMedCentral
6.
go back to reference Chen T, Surcel HM, Lundin E. Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 2011;20(2):324–36.CrossRef Chen T, Surcel HM, Lundin E. Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 2011;20(2):324–36.CrossRef
7.
go back to reference Sanchez-Zamorano LM, Salazar-Martinez E, De Los Rios PE, Gonzalez-Lira G, Flores-Luna L, Lazcano-Ponce EC. Factors associated with non-epithelial ovarian cancer among Mexican women: a matched case-control study. Int J Gynecol Cancer. 2003;13(6):756–63.CrossRefPubMed Sanchez-Zamorano LM, Salazar-Martinez E, De Los Rios PE, Gonzalez-Lira G, Flores-Luna L, Lazcano-Ponce EC. Factors associated with non-epithelial ovarian cancer among Mexican women: a matched case-control study. Int J Gynecol Cancer. 2003;13(6):756–63.CrossRefPubMed
8.
go back to reference Albrektsen G, Heuch I, Kvåle G. Full-term pregnancies and incidence of ovarian cancer of stromal and germ cell origin: a Norwegian prospective study. Br J Cancer. 1997;75(5):767–70.CrossRefPubMedPubMedCentral Albrektsen G, Heuch I, Kvåle G. Full-term pregnancies and incidence of ovarian cancer of stromal and germ cell origin: a Norwegian prospective study. Br J Cancer. 1997;75(5):767–70.CrossRefPubMedPubMedCentral
9.
go back to reference Smith HO, Berwick M, Verschraegen CF. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075–85.CrossRefPubMed Smith HO, Berwick M, Verschraegen CF. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075–85.CrossRefPubMed
10.
go back to reference dos Santos Silva I, Swerdlow AJ. Ovarian germ cell malignancies in England: epidemiological parallels with testicular cancer. Br J Cancer. 1991;63(5):814–8.CrossRefPubMedPubMedCentral dos Santos Silva I, Swerdlow AJ. Ovarian germ cell malignancies in England: epidemiological parallels with testicular cancer. Br J Cancer. 1991;63(5):814–8.CrossRefPubMedPubMedCentral
11.
go back to reference Ugianskiene A, Grove A, Soegaard-Andersen E. Adult granulosa cell tumor of the ovary: a retrospective study of 37 cases. Eur J Gynaecol Oncol. 2014;35(6):621–4.PubMed Ugianskiene A, Grove A, Soegaard-Andersen E. Adult granulosa cell tumor of the ovary: a retrospective study of 37 cases. Eur J Gynaecol Oncol. 2014;35(6):621–4.PubMed
12.
go back to reference van Meurs HS, Buist MR, Westermann AM, Sonke GS, Kenter GG, van der Velden J. Effectiveness of chemotherapy in measurable granulosa cell tumors: a retrospective study and review of literature. Int J Gynecol Cancer. 2014;24(3):496–505.CrossRefPubMed van Meurs HS, Buist MR, Westermann AM, Sonke GS, Kenter GG, van der Velden J. Effectiveness of chemotherapy in measurable granulosa cell tumors: a retrospective study and review of literature. Int J Gynecol Cancer. 2014;24(3):496–505.CrossRefPubMed
13.
go back to reference Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21(6):1180–9 (Review).CrossRefPubMed Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21(6):1180–9 (Review).CrossRefPubMed
14.
go back to reference Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol. 2004;22(17):3517–23.CrossRefPubMed Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol. 2004;22(17):3517–23.CrossRefPubMed
15.
go back to reference Freeman SA, Modesitt SC. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecol Oncol. 2006;103(2):755–8.CrossRefPubMed Freeman SA, Modesitt SC. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecol Oncol. 2006;103(2):755–8.CrossRefPubMed
16.
go back to reference Rogers PC, Olson TA, Cullen JW, Billmire DF, Marina N, Rescorla F, et al. Pediatric Oncology Group 9048; Children’s Cancer Group 8891. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: a Pediatric Intergroup Study—Pediatric Oncology Group 9048 and Children’s Cancer Group 8891. J Clin Oncol. 2004;22(17):3563–9.CrossRefPubMed Rogers PC, Olson TA, Cullen JW, Billmire DF, Marina N, Rescorla F, et al. Pediatric Oncology Group 9048; Children’s Cancer Group 8891. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: a Pediatric Intergroup Study—Pediatric Oncology Group 9048 and Children’s Cancer Group 8891. J Clin Oncol. 2004;22(17):3563–9.CrossRefPubMed
17.
go back to reference Zanetta G, Bonazzi C, Cantù M, Binidagger S, Locatelli A, Bratina G, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol. 2001;19(4):1015–20.PubMed Zanetta G, Bonazzi C, Cantù M, Binidagger S, Locatelli A, Bratina G, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol. 2001;19(4):1015–20.PubMed
18.
go back to reference Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children’s Oncology Group. J Clin Oncol. 2014;32(5):465–70.CrossRefPubMedPubMedCentral Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children’s Oncology Group. J Clin Oncol. 2014;32(5):465–70.CrossRefPubMedPubMedCentral
19.
go back to reference Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24(30):4862–6.CrossRefPubMed Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24(30):4862–6.CrossRefPubMed
20.
go back to reference Mutch DG, Prat J. FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401–4.CrossRefPubMed Mutch DG, Prat J. FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401–4.CrossRefPubMed
21.
go back to reference Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.CrossRefPubMed Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.CrossRefPubMed
22.
go back to reference Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C, ESMO Guidelines Working Group. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;Suppl7:vii20–6. Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C, ESMO Guidelines Working Group. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;Suppl7:vii20–6.
23.
go back to reference Yang ZJ, Liu ZC, Wei RJ, Li L. An analysis of prognostic factors in patients with ovarian Malignant germ cell tumors who are treated with fertility-preserving surgery. Gynecol Obstet Invest. 2015;81(1):1–9.CrossRefPubMed Yang ZJ, Liu ZC, Wei RJ, Li L. An analysis of prognostic factors in patients with ovarian Malignant germ cell tumors who are treated with fertility-preserving surgery. Gynecol Obstet Invest. 2015;81(1):1–9.CrossRefPubMed
24.
go back to reference Bilici A, Inanc M, Ulas A, Akman T, Seker M, Babacan NA, et al. Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology. Asian Pac J Cancer Prev. 2014;14(11):6493–9.CrossRefPubMed Bilici A, Inanc M, Ulas A, Akman T, Seker M, Babacan NA, et al. Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology. Asian Pac J Cancer Prev. 2014;14(11):6493–9.CrossRefPubMed
25.
go back to reference Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, et al. Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953–2009). Gynecol Oncol. 2013;131(2):330–5.CrossRefPubMed Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, et al. Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953–2009). Gynecol Oncol. 2013;131(2):330–5.CrossRefPubMed
26.
go back to reference da Silva Lopes. J, Luiz Renna N Jr, Paulino E, de Melo AC. Outcomes of ovarian germ cell tumors: ten years of experience at the Brazilian National Cancer Institute. Int J Gynecol Cancer. 2015;25(5):786–91.CrossRef da Silva Lopes. J, Luiz Renna N Jr, Paulino E, de Melo AC. Outcomes of ovarian germ cell tumors: ten years of experience at the Brazilian National Cancer Institute. Int J Gynecol Cancer. 2015;25(5):786–91.CrossRef
27.
go back to reference Billmire DF, Krailo M, Rodriguez-Galindo C, Frazier AL, et al. Reply to G. Mangili and C. Lhommé et al. J Clin Oncol. 2014;32(25):2816–7.CrossRefPubMed Billmire DF, Krailo M, Rodriguez-Galindo C, Frazier AL, et al. Reply to G. Mangili and C. Lhommé et al. J Clin Oncol. 2014;32(25):2816–7.CrossRefPubMed
28.
go back to reference Ray-Coquard I, Weber B, Lotz JP. Management of rare ovarian cancers: the experience of the French website “Observatory for rare malignant tumours of the ovaries” by the GINECO group: interim analysis of the first 100 patients. Gynecol Oncol. 2010;119(1):53–9.CrossRefPubMed Ray-Coquard I, Weber B, Lotz JP. Management of rare ovarian cancers: the experience of the French website “Observatory for rare malignant tumours of the ovaries” by the GINECO group: interim analysis of the first 100 patients. Gynecol Oncol. 2010;119(1):53–9.CrossRefPubMed
Metadata
Title
Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience
Authors
E. Kempf
G. Desamericq
B. Vieites
I. Diaz-Padilla
E. Calvo
P. Estevez
A. Garcia-Arreza
M.A. Martinez-Maestre
I. Duran
Publication date
01-02-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 2/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1517-x

Other articles of this Issue 2/2017

Clinical and Translational Oncology 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine